Misryoum unpacks why the FDA rejected RP1 despite trial promise and what the decision signals for future melanoma approvals.
A promising melanoma therapy hit a major regulatory roadblock when the FDA rejected RP1, an oncolytic immunotherapy being developed for patients whose cancers have not responded to standard treatment.
In this context, RP1’s story has become a flashpoint for both clinicians and biotech developers.. Misryoum reports that the drug received a fast-track “breakthrough” designation after early trial results suggested meaningful responses in advanced melanoma.. Yet as 2024 development accelerated toward approval. the FDA declined approval twice. leaving the research team and the wider oncology community questioning what standards—and expectations—are being applied.
At the heart of the controversy is how well the trial results could be interpreted as coming from RP1 itself.. Misryoum notes that the FDA’s review cited issues with the trial population being too varied. including differences in patients’ prior therapies and disease characteristics.. Reviewers also questioned whether the apparent benefit could be attributed to RP1 when patients were receiving RP1 alongside a commonly used immunotherapy drug. rather than being driven primarily by that background treatment.
For doctors, though, RP1 was designed for a group that often has few options left.. In advanced melanoma that no longer responds to first-line care. the clinical challenge is not only whether a treatment can work. but whether it can offer a meaningful alternative when standard approaches fail.. Meanwhile. for drug developers. regulatory expectations like trial design and control strategies can determine whether promising results translate into a path toward approval.
RP1 works by using an engineered virus—based on a modified herpesvirus—delivered directly into tumors.. The idea is to trigger cancer cell destruction and. in the process. stimulate the immune system to recognize and attack related cancer cells.. In the IGNYTE phase 1/2 trial. the combination of RP1 and nivolumab showed better improvement rates than nivolumab alone in a similar group. according to the reporting Misryoum reviewed.. An FDA panel reviewing the study had recommended approval. but later the FDA issued a complete response letter. effectively saying more evidence or different data interpretation would be needed.
The FDA’s main concern also touches an ethical dilemma that affects how oncology trials are designed.. A placebo-controlled approach would not be realistic for patients in this setting. because participants were required to have already tried therapies like nivolumab without improvement.. That meant the study lacked a placebo arm in which patients would receive an inactive substitute instead of RP1—an omission the FDA said made it harder to isolate the treatment effect specifically to RP1.
Misryoum also reports that after the first rejection. the company resubmitted with added analyses and information from an ongoing phase 3 effort.. A second complete response letter reiterated similar concerns while also pointing to process-related changes. including the oversight team being updated before the resubmission was evaluated.. This combination of shifting feedback and persistent trial-design questions has intensified frustration among researchers and patients who argue that RP1 appears well tolerated and potentially beneficial in a population with limited alternatives.
Beyond RP1. the fallout raises broader questions about how cancer therapies—especially those meant for treatment-resistant disease—will be judged in the future.. If expectations for trial structure and evidentiary “cleanliness” become harder to meet in real-world. hard-to-randomize populations. developers may face longer delays translating clinical promise into approvals.
In the end. what looks like one drug’s rejection may be read as a signal about regulatory direction for melanoma and other advanced cancers.. Misryoum’s view is that clarity on what “enough evidence” means—how trial heterogeneity is handled and how treatment effects are attributed—could be just as important as the therapies themselves.